Matthew McQueen
Concepts (508)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome-Wide Association Study | 22 | 2022 | 1428 | 1.950 |
Why?
| | Polymorphism, Single Nucleotide | 40 | 2020 | 2184 | 1.760 |
Why?
| | Genetic Predisposition to Disease | 26 | 2022 | 2412 | 1.400 |
Why?
| | Genetic Linkage | 10 | 2011 | 297 | 1.320 |
Why?
| | Troponin I | 9 | 2020 | 81 | 1.150 |
Why?
| | Troponin T | 9 | 2020 | 65 | 1.080 |
Why?
| | Waist-Height Ratio | 3 | 2016 | 7 | 1.030 |
Why?
| | Risk-Taking | 4 | 2015 | 347 | 0.840 |
Why?
| | Body Mass Index | 12 | 2015 | 2375 | 0.810 |
Why?
| | Genetic Testing | 9 | 2016 | 453 | 0.730 |
Why?
| | Acute Coronary Syndrome | 6 | 2020 | 275 | 0.720 |
Why?
| | Sexual Behavior | 3 | 2013 | 484 | 0.680 |
Why?
| | Bipolar Disorder | 5 | 2011 | 264 | 0.650 |
Why?
| | Alcohol Drinking | 7 | 2022 | 820 | 0.650 |
Why?
| | Siblings | 7 | 2014 | 227 | 0.640 |
Why?
| | Quantitative Trait, Heritable | 5 | 2016 | 125 | 0.590 |
Why?
| | Myocardial Infarction | 10 | 2020 | 1041 | 0.580 |
Why?
| | Epidemiology | 1 | 2018 | 33 | 0.570 |
Why?
| | Genome, Human | 9 | 2014 | 423 | 0.570 |
Why?
| | Genotype | 18 | 2019 | 1914 | 0.570 |
Why?
| | Cardiovascular Diseases | 13 | 2024 | 2104 | 0.560 |
Why?
| | Substance-Related Disorders | 8 | 2020 | 1069 | 0.550 |
Why?
| | Metabolic Syndrome | 2 | 2016 | 354 | 0.540 |
Why?
| | Quantitative Trait Loci | 4 | 2015 | 380 | 0.540 |
Why?
| | Brain Concussion | 2 | 2021 | 573 | 0.510 |
Why?
| | Databases, Genetic | 5 | 2012 | 237 | 0.500 |
Why?
| | Alzheimer Disease | 8 | 2011 | 558 | 0.500 |
Why?
| | Teaching | 1 | 2018 | 224 | 0.490 |
Why?
| | Longitudinal Studies | 15 | 2024 | 2829 | 0.490 |
Why?
| | Antisocial Personality Disorder | 2 | 2015 | 168 | 0.480 |
Why?
| | Education, Medical, Undergraduate | 1 | 2018 | 184 | 0.480 |
Why?
| | Alcoholism | 8 | 2020 | 804 | 0.470 |
Why?
| | Waist Circumference | 1 | 2015 | 143 | 0.470 |
Why?
| | Receptors, Nicotinic | 7 | 2013 | 334 | 0.470 |
Why?
| | Athletic Injuries | 2 | 2021 | 526 | 0.470 |
Why?
| | Humans | 122 | 2024 | 136765 | 0.470 |
Why?
| | Genetic Variation | 8 | 2022 | 985 | 0.450 |
Why?
| | Obesity | 9 | 2016 | 2982 | 0.430 |
Why?
| | Tobacco Use Disorder | 6 | 2020 | 251 | 0.430 |
Why?
| | Impulsive Behavior | 1 | 2015 | 149 | 0.410 |
Why?
| | Gene-Environment Interaction | 2 | 2014 | 190 | 0.410 |
Why?
| | Predictive Value of Tests | 4 | 2020 | 2022 | 0.410 |
Why?
| | Public Health | 1 | 2018 | 579 | 0.400 |
Why?
| | Blood Pressure | 8 | 2018 | 1774 | 0.400 |
Why?
| | Male | 74 | 2024 | 67311 | 0.390 |
Why?
| | Aging | 6 | 2020 | 1864 | 0.390 |
Why?
| | Conduct Disorder | 5 | 2015 | 201 | 0.380 |
Why?
| | Female | 71 | 2024 | 72795 | 0.370 |
Why?
| | Breast Feeding | 1 | 2015 | 439 | 0.370 |
Why?
| | Natriuretic Peptide, Brain | 4 | 2024 | 99 | 0.360 |
Why?
| | Phenotype | 17 | 2020 | 3189 | 0.350 |
Why?
| | Sodium, Dietary | 4 | 2018 | 41 | 0.350 |
Why?
| | Genetic Loci | 4 | 2022 | 288 | 0.350 |
Why?
| | Carrier State | 2 | 2021 | 67 | 0.340 |
Why?
| | Sodium | 3 | 2018 | 216 | 0.340 |
Why?
| | Chromosomes, Human, Pair 6 | 2 | 2010 | 52 | 0.320 |
Why?
| | Myocardium | 3 | 2020 | 1001 | 0.310 |
Why?
| | Clinical Laboratory Techniques | 3 | 2020 | 97 | 0.310 |
Why?
| | Pedigree | 3 | 2013 | 514 | 0.300 |
Why?
| | Adult | 36 | 2020 | 37631 | 0.300 |
Why?
| | Apolipoprotein E4 | 2 | 2007 | 37 | 0.290 |
Why?
| | Risk Factors | 26 | 2022 | 10325 | 0.290 |
Why?
| | Apolipoprotein E2 | 1 | 2007 | 3 | 0.290 |
Why?
| | alpha-Macroglobulins | 1 | 2007 | 24 | 0.280 |
Why?
| | Biometry | 2 | 2007 | 70 | 0.280 |
Why?
| | Adolescent | 25 | 2021 | 21382 | 0.270 |
Why?
| | Young Adult | 17 | 2021 | 13127 | 0.270 |
Why?
| | Body Weight | 5 | 2015 | 985 | 0.270 |
Why?
| | Emergency Service, Hospital | 8 | 2020 | 2046 | 0.270 |
Why?
| | Middle Aged | 35 | 2024 | 33228 | 0.260 |
Why?
| | Multifactorial Inheritance | 2 | 2022 | 174 | 0.260 |
Why?
| | Blood Glucose | 9 | 2018 | 2181 | 0.260 |
Why?
| | Family | 7 | 2011 | 665 | 0.250 |
Why?
| | Aged | 32 | 2024 | 23794 | 0.250 |
Why?
| | Memory | 1 | 2007 | 248 | 0.240 |
Why?
| | Linkage Disequilibrium | 7 | 2020 | 268 | 0.240 |
Why?
| | Chromosomes, Human, Pair 8 | 1 | 2005 | 36 | 0.240 |
Why?
| | Sodium Nitrite | 2 | 2015 | 39 | 0.240 |
Why?
| | Models, Genetic | 8 | 2016 | 599 | 0.230 |
Why?
| | Biomarkers | 11 | 2024 | 4144 | 0.230 |
Why?
| | Asymptomatic Infections | 2 | 2021 | 30 | 0.230 |
Why?
| | Filgrastim | 1 | 2024 | 8 | 0.230 |
Why?
| | Diet, Sodium-Restricted | 2 | 2016 | 36 | 0.220 |
Why?
| | Endothelium, Vascular | 3 | 2016 | 926 | 0.220 |
Why?
| | HIV Infections | 3 | 2013 | 2828 | 0.220 |
Why?
| | Internationality | 2 | 2022 | 154 | 0.220 |
Why?
| | Feeding and Eating Disorders | 2 | 2020 | 152 | 0.220 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2024 | 23 | 0.220 |
Why?
| | Heart Diseases | 2 | 2017 | 346 | 0.220 |
Why?
| | Health Status | 2 | 2018 | 788 | 0.210 |
Why?
| | Population Health | 1 | 2024 | 47 | 0.200 |
Why?
| | ROC Curve | 4 | 2017 | 545 | 0.200 |
Why?
| | Cooperative Behavior | 1 | 2005 | 445 | 0.200 |
Why?
| | Viral Load | 2 | 2021 | 464 | 0.200 |
Why?
| | Prospective Studies | 10 | 2021 | 7572 | 0.200 |
Why?
| | Cholesterol, HDL | 3 | 2016 | 203 | 0.190 |
Why?
| | Saliva | 2 | 2021 | 242 | 0.190 |
Why?
| | Reproducibility of Results | 3 | 2021 | 3265 | 0.190 |
Why?
| | Nerve Tissue Proteins | 4 | 2011 | 595 | 0.190 |
Why?
| | Tobacco Use | 1 | 2022 | 64 | 0.190 |
Why?
| | Case-Control Studies | 15 | 2019 | 3539 | 0.190 |
Why?
| | Lipids | 3 | 2018 | 665 | 0.190 |
Why?
| | Peptide Fragments | 4 | 2024 | 705 | 0.180 |
Why?
| | Neuropsychological Tests | 2 | 2021 | 1022 | 0.180 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 2 | 2012 | 75 | 0.180 |
Why?
| | Glomerular Filtration Rate | 4 | 2018 | 745 | 0.170 |
Why?
| | Gastrointestinal Microbiome | 2 | 2020 | 697 | 0.170 |
Why?
| | Prediabetic State | 1 | 2024 | 253 | 0.170 |
Why?
| | Mental Disorders | 3 | 2019 | 1070 | 0.170 |
Why?
| | Hypertension | 4 | 2016 | 1284 | 0.170 |
Why?
| | Receptors, GABA-A | 2 | 2014 | 142 | 0.170 |
Why?
| | Alleles | 5 | 2018 | 890 | 0.170 |
Why?
| | Diseases in Twins | 2 | 2012 | 169 | 0.170 |
Why?
| | Smoking | 5 | 2019 | 1620 | 0.170 |
Why?
| | Gene Frequency | 10 | 2011 | 520 | 0.170 |
Why?
| | Brachial Artery | 3 | 2016 | 201 | 0.160 |
Why?
| | Risk | 4 | 2020 | 908 | 0.160 |
Why?
| | Immunoassay | 1 | 2020 | 113 | 0.160 |
Why?
| | Multigene Family | 2 | 2011 | 198 | 0.160 |
Why?
| | Risk Assessment | 8 | 2020 | 3432 | 0.150 |
Why?
| | Reference Values | 4 | 2016 | 816 | 0.150 |
Why?
| | Genetic Markers | 4 | 2014 | 344 | 0.150 |
Why?
| | Surgical Procedures, Operative | 2 | 2014 | 258 | 0.150 |
Why?
| | Polyethylene Glycols | 1 | 2024 | 640 | 0.150 |
Why?
| | Minisatellite Repeats | 1 | 2019 | 42 | 0.150 |
Why?
| | Data Interpretation, Statistical | 3 | 2011 | 363 | 0.150 |
Why?
| | Diagnostic Tests, Routine | 1 | 2020 | 110 | 0.150 |
Why?
| | Global Health | 4 | 2016 | 385 | 0.150 |
Why?
| | Behavior | 1 | 2019 | 90 | 0.150 |
Why?
| | Schizophrenia | 3 | 2020 | 438 | 0.140 |
Why?
| | Healthy Aging | 1 | 2018 | 35 | 0.140 |
Why?
| | Adolescent Behavior | 2 | 2013 | 529 | 0.140 |
Why?
| | Biological Specimen Banks | 1 | 2019 | 102 | 0.140 |
Why?
| | Feces | 2 | 2020 | 481 | 0.140 |
Why?
| | Pandemics | 2 | 2024 | 1612 | 0.140 |
Why?
| | Vascular Stiffness | 3 | 2018 | 493 | 0.140 |
Why?
| | Genetic Association Studies | 4 | 2014 | 375 | 0.140 |
Why?
| | Sodium Pertechnetate Tc 99m | 2 | 1997 | 4 | 0.140 |
Why?
| | Students | 2 | 2021 | 624 | 0.140 |
Why?
| | Marijuana Abuse | 1 | 2020 | 232 | 0.140 |
Why?
| | Body Height | 2 | 2015 | 199 | 0.140 |
Why?
| | NAD | 1 | 2018 | 77 | 0.140 |
Why?
| | Likelihood Functions | 2 | 2015 | 143 | 0.140 |
Why?
| | Niacinamide | 1 | 2018 | 79 | 0.140 |
Why?
| | Exercise | 3 | 2018 | 2043 | 0.140 |
Why?
| | Caloric Restriction | 2 | 2018 | 123 | 0.140 |
Why?
| | Athletes | 1 | 2021 | 422 | 0.130 |
Why?
| | Burns | 1 | 2021 | 325 | 0.130 |
Why?
| | Mouth | 1 | 2017 | 87 | 0.130 |
Why?
| | Apolipoprotein B-100 | 1 | 2016 | 10 | 0.130 |
Why?
| | Cholesterol, LDL | 2 | 2016 | 365 | 0.130 |
Why?
| | Hair | 2 | 2015 | 84 | 0.130 |
Why?
| | Psychological Trauma | 1 | 2017 | 55 | 0.130 |
Why?
| | Regional Blood Flow | 2 | 2016 | 473 | 0.130 |
Why?
| | Apolipoprotein A-I | 1 | 2016 | 30 | 0.130 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2016 | 40 | 0.130 |
Why?
| | Cognitive Dysfunction | 1 | 2022 | 381 | 0.130 |
Why?
| | Trehalose | 1 | 2016 | 32 | 0.130 |
Why?
| | Chromosome Mapping | 5 | 2015 | 523 | 0.130 |
Why?
| | Receptors, Metabotropic Glutamate | 1 | 2016 | 40 | 0.130 |
Why?
| | Europe | 5 | 2022 | 413 | 0.120 |
Why?
| | Gene Regulatory Networks | 2 | 2018 | 304 | 0.120 |
Why?
| | Cross-Sectional Studies | 6 | 2013 | 5423 | 0.120 |
Why?
| | Algorithms | 3 | 2020 | 1689 | 0.120 |
Why?
| | Aged, 80 and over | 7 | 2020 | 7585 | 0.120 |
Why?
| | Cohort Studies | 9 | 2020 | 5701 | 0.120 |
Why?
| | Sexual Partners | 2 | 2013 | 186 | 0.120 |
Why?
| | United States | 5 | 2016 | 14690 | 0.110 |
Why?
| | Amino Acids | 1 | 2018 | 497 | 0.110 |
Why?
| | Educational Status | 2 | 2014 | 470 | 0.110 |
Why?
| | Adolescent Medicine | 1 | 2014 | 30 | 0.110 |
Why?
| | Quality Control | 1 | 2014 | 171 | 0.110 |
Why?
| | Carotid Arteries | 1 | 2015 | 206 | 0.110 |
Why?
| | Health Surveys | 1 | 2016 | 513 | 0.110 |
Why?
| | Proteome | 1 | 2018 | 472 | 0.110 |
Why?
| | Odds Ratio | 6 | 2016 | 1065 | 0.110 |
Why?
| | Malawi | 1 | 2013 | 53 | 0.100 |
Why?
| | Hindlimb | 1 | 2014 | 128 | 0.100 |
Why?
| | Albuminuria | 1 | 2014 | 185 | 0.100 |
Why?
| | Income | 1 | 2014 | 202 | 0.100 |
Why?
| | Locomotion | 1 | 2014 | 106 | 0.100 |
Why?
| | Nervous System Physiological Phenomena | 1 | 2013 | 21 | 0.100 |
Why?
| | Colorado | 4 | 2021 | 4515 | 0.100 |
Why?
| | Aorta | 1 | 2015 | 417 | 0.100 |
Why?
| | Telomere | 1 | 2016 | 280 | 0.100 |
Why?
| | Metabolomics | 1 | 2018 | 678 | 0.100 |
Why?
| | Polymorphism, Genetic | 3 | 2012 | 659 | 0.100 |
Why?
| | Metformin | 1 | 2016 | 330 | 0.100 |
Why?
| | Physical Exertion | 1 | 2014 | 215 | 0.100 |
Why?
| | Transplantation | 1 | 2013 | 34 | 0.100 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 131 | 0.100 |
Why?
| | Metabolic Networks and Pathways | 1 | 2014 | 180 | 0.100 |
Why?
| | Double-Blind Method | 5 | 2018 | 1981 | 0.100 |
Why?
| | Hypoglycemic Agents | 2 | 2024 | 1283 | 0.100 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2024 | 2518 | 0.100 |
Why?
| | Myocardial Ischemia | 1 | 2014 | 262 | 0.100 |
Why?
| | DEAD-box RNA Helicases | 1 | 2013 | 76 | 0.100 |
Why?
| | Cardiac Surgical Procedures | 1 | 2018 | 530 | 0.090 |
Why?
| | Substance Abuse, Intravenous | 1 | 2013 | 114 | 0.090 |
Why?
| | Pravastatin | 1 | 1992 | 41 | 0.090 |
Why?
| | Receptors, Oxytocin | 1 | 2012 | 23 | 0.090 |
Why?
| | Lovastatin | 1 | 1992 | 37 | 0.090 |
Why?
| | Genetic Heterogeneity | 3 | 2008 | 59 | 0.090 |
Why?
| | Canada | 5 | 2007 | 417 | 0.090 |
Why?
| | Prevalence | 6 | 2017 | 2710 | 0.090 |
Why?
| | Hyperlipoproteinemia Type II | 1 | 1992 | 35 | 0.090 |
Why?
| | Puberty | 1 | 2013 | 146 | 0.090 |
Why?
| | Age Factors | 6 | 2020 | 3284 | 0.090 |
Why?
| | Haplotypes | 6 | 2010 | 494 | 0.090 |
Why?
| | Sensitivity and Specificity | 3 | 2021 | 1935 | 0.090 |
Why?
| | Ramipril | 2 | 2008 | 6 | 0.090 |
Why?
| | Physical Fitness | 1 | 2013 | 208 | 0.090 |
Why?
| | Chromosomes, Human, Pair 18 | 1 | 2011 | 10 | 0.090 |
Why?
| | Postural Balance | 1 | 2014 | 216 | 0.090 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2011 | 41 | 0.090 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2011 | 55 | 0.090 |
Why?
| | Potassium | 1 | 2011 | 147 | 0.090 |
Why?
| | Software | 2 | 2014 | 665 | 0.090 |
Why?
| | Interleukins | 1 | 2013 | 250 | 0.090 |
Why?
| | Receptors, Immunologic | 2 | 2013 | 216 | 0.090 |
Why?
| | Receptors, Dopamine D4 | 1 | 2011 | 26 | 0.090 |
Why?
| | Glucose Metabolism Disorders | 1 | 2010 | 11 | 0.090 |
Why?
| | Behavior, Animal | 1 | 2014 | 497 | 0.090 |
Why?
| | Diabetes Mellitus | 3 | 2011 | 1032 | 0.090 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2011 | 57 | 0.090 |
Why?
| | Motor Activity | 1 | 2015 | 717 | 0.090 |
Why?
| | Follow-Up Studies | 6 | 2024 | 5106 | 0.080 |
Why?
| | Child Behavior Disorders | 1 | 2011 | 144 | 0.080 |
Why?
| | Catechol O-Methyltransferase | 1 | 2010 | 17 | 0.080 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2008 | 201 | 0.080 |
Why?
| | Hepatitis C | 1 | 2013 | 267 | 0.080 |
Why?
| | Diet, Reducing | 1 | 2010 | 89 | 0.080 |
Why?
| | Life Expectancy | 1 | 2010 | 68 | 0.080 |
Why?
| | Quality of Life | 1 | 2021 | 2878 | 0.080 |
Why?
| | Tissue Donors | 1 | 2013 | 417 | 0.080 |
Why?
| | Psychology, Adolescent | 1 | 2009 | 66 | 0.080 |
Why?
| | Microbiota | 1 | 2017 | 762 | 0.080 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2017 | 842 | 0.080 |
Why?
| | Twins, Dizygotic | 1 | 2010 | 175 | 0.080 |
Why?
| | Environment | 2 | 2010 | 357 | 0.080 |
Why?
| | Isotretinoin | 1 | 2009 | 26 | 0.080 |
Why?
| | Hyperhomocysteinemia | 1 | 2009 | 27 | 0.080 |
Why?
| | Insulin Glargine | 2 | 2022 | 84 | 0.080 |
Why?
| | Twins, Monozygotic | 1 | 2010 | 203 | 0.080 |
Why?
| | Acne Vulgaris | 1 | 2009 | 28 | 0.080 |
Why?
| | Hypertriglyceridemia | 1 | 2009 | 39 | 0.080 |
Why?
| | Energy Metabolism | 1 | 2015 | 919 | 0.080 |
Why?
| | Ontario | 2 | 2020 | 147 | 0.080 |
Why?
| | Genes, Neoplasm | 1 | 2008 | 22 | 0.070 |
Why?
| | Longevity | 1 | 2010 | 164 | 0.070 |
Why?
| | Benzoates | 1 | 2008 | 43 | 0.070 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 5742 | 0.070 |
Why?
| | Homocysteine | 1 | 2009 | 156 | 0.070 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 38 | 0.070 |
Why?
| | Dermatologic Agents | 1 | 2009 | 69 | 0.070 |
Why?
| | Raphe Nuclei | 2 | 1999 | 110 | 0.070 |
Why?
| | Myosin Type V | 1 | 2008 | 9 | 0.070 |
Why?
| | Proteinuria | 1 | 2008 | 97 | 0.070 |
Why?
| | Universities | 2 | 2021 | 433 | 0.070 |
Why?
| | Cognition | 1 | 2015 | 1146 | 0.070 |
Why?
| | Vitamins | 1 | 2009 | 185 | 0.070 |
Why?
| | Benzimidazoles | 1 | 2008 | 170 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2013 | 2822 | 0.070 |
Why?
| | Death | 2 | 2018 | 119 | 0.070 |
Why?
| | Prognosis | 4 | 2021 | 4013 | 0.070 |
Why?
| | Myosin Heavy Chains | 1 | 2008 | 191 | 0.070 |
Why?
| | Atrial Natriuretic Factor | 1 | 2006 | 57 | 0.060 |
Why?
| | Triglycerides | 2 | 2003 | 524 | 0.060 |
Why?
| | Task Performance and Analysis | 1 | 2007 | 183 | 0.060 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2011 | 413 | 0.060 |
Why?
| | China | 3 | 2007 | 216 | 0.060 |
Why?
| | Sex Factors | 4 | 2017 | 2060 | 0.060 |
Why?
| | Pharmacogenetics | 1 | 2007 | 179 | 0.060 |
Why?
| | Parkinson Disease | 1 | 2012 | 490 | 0.060 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2005 | 30 | 0.060 |
Why?
| | Heart Failure | 2 | 2011 | 2231 | 0.060 |
Why?
| | Lipoproteins, LDL | 1 | 2005 | 116 | 0.060 |
Why?
| | Antigens, Neoplasm | 1 | 2008 | 319 | 0.060 |
Why?
| | Membrane Glycoproteins | 1 | 2008 | 500 | 0.060 |
Why?
| | Liver Transplantation | 1 | 2013 | 871 | 0.060 |
Why?
| | Biological Availability | 2 | 2012 | 148 | 0.060 |
Why?
| | Hematologic Agents | 1 | 2024 | 2 | 0.060 |
Why?
| | Febrile Neutropenia | 1 | 2024 | 6 | 0.060 |
Why?
| | Chemical Phenomena | 1 | 2024 | 83 | 0.060 |
Why?
| | ErbB Receptors | 1 | 2008 | 613 | 0.060 |
Why?
| | Ankle Brachial Index | 1 | 2024 | 37 | 0.050 |
Why?
| | Comorbidity | 4 | 2013 | 1614 | 0.050 |
Why?
| | Stroke | 2 | 2011 | 1118 | 0.050 |
Why?
| | Anxiety Disorders | 2 | 2021 | 374 | 0.050 |
Why?
| | Metabolome | 2 | 2018 | 350 | 0.050 |
Why?
| | Tobacco Products | 2 | 2019 | 136 | 0.050 |
Why?
| | Cognition Disorders | 1 | 2007 | 495 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 208 | 0.050 |
Why?
| | Chlamydophila Infections | 1 | 2003 | 5 | 0.050 |
Why?
| | Analysis of Variance | 1 | 2006 | 1316 | 0.050 |
Why?
| | Telephone | 1 | 2024 | 170 | 0.050 |
Why?
| | Hepatitis A | 1 | 2003 | 26 | 0.050 |
Why?
| | Helicobacter Infections | 1 | 2003 | 32 | 0.050 |
Why?
| | Muscle, Skeletal | 1 | 2013 | 1710 | 0.050 |
Why?
| | Arteriosclerosis | 1 | 2003 | 88 | 0.050 |
Why?
| | Sample Size | 1 | 2022 | 125 | 0.050 |
Why?
| | Time Factors | 3 | 2020 | 6808 | 0.050 |
Why?
| | Child | 8 | 2021 | 21819 | 0.050 |
Why?
| | Depressive Disorder, Major | 2 | 2020 | 362 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2014 | 2639 | 0.050 |
Why?
| | Mental Status and Dementia Tests | 1 | 2022 | 26 | 0.050 |
Why?
| | Evaluation Studies as Topic | 2 | 2020 | 180 | 0.050 |
Why?
| | C-Reactive Protein | 1 | 2024 | 408 | 0.050 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2024 | 610 | 0.050 |
Why?
| | Incidence | 2 | 2019 | 2792 | 0.050 |
Why?
| | Logistic Models | 2 | 2016 | 2067 | 0.040 |
Why?
| | Kidney Diseases | 1 | 2005 | 407 | 0.040 |
Why?
| | Dietary Supplements | 2 | 2015 | 559 | 0.040 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2021 | 37 | 0.040 |
Why?
| | Pilot Projects | 2 | 2017 | 1692 | 0.040 |
Why?
| | Cytomegalovirus Infections | 1 | 2003 | 192 | 0.040 |
Why?
| | Virion | 1 | 2021 | 91 | 0.040 |
Why?
| | Kidney | 1 | 2008 | 1467 | 0.040 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 2 | 2013 | 243 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 2052 | 0.040 |
Why?
| | Patient Selection | 2 | 2008 | 690 | 0.040 |
Why?
| | Luminescence | 1 | 2020 | 38 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2021 | 105 | 0.040 |
Why?
| | Serotonin | 2 | 1999 | 323 | 0.040 |
Why?
| | Electrochemical Techniques | 1 | 2020 | 52 | 0.040 |
Why?
| | Polymerase Chain Reaction | 2 | 2014 | 1059 | 0.040 |
Why?
| | Specimen Handling | 1 | 2021 | 181 | 0.040 |
Why?
| | Opioid Peptides | 1 | 1999 | 9 | 0.040 |
Why?
| | Computer Simulation | 3 | 2010 | 973 | 0.040 |
Why?
| | Hyperglycemia | 1 | 2003 | 347 | 0.040 |
Why?
| | Escape Reaction | 1 | 1999 | 62 | 0.040 |
Why?
| | Asia, Southeastern | 1 | 1998 | 13 | 0.040 |
Why?
| | Apolipoproteins | 2 | 2004 | 33 | 0.040 |
Why?
| | Genetics, Behavioral | 1 | 2019 | 36 | 0.040 |
Why?
| | Helplessness, Learned | 1 | 1999 | 68 | 0.040 |
Why?
| | Potassium, Dietary | 1 | 2018 | 12 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2020 | 404 | 0.040 |
Why?
| | Pyridinium Compounds | 1 | 2018 | 26 | 0.040 |
Why?
| | Infusions, Intravenous | 2 | 1997 | 412 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1501 | 0.040 |
Why?
| | United Kingdom | 1 | 2019 | 310 | 0.040 |
Why?
| | Oxidative Stress | 2 | 2016 | 1314 | 0.030 |
Why?
| | Methionine | 1 | 2018 | 160 | 0.030 |
Why?
| | Limit of Detection | 1 | 2017 | 85 | 0.030 |
Why?
| | Chromosomes, Human | 1 | 2017 | 44 | 0.030 |
Why?
| | Erythrocyte Count | 1 | 2017 | 20 | 0.030 |
Why?
| | Transcription Factors | 1 | 2005 | 1718 | 0.030 |
Why?
| | Hospitalization | 2 | 2021 | 2182 | 0.030 |
Why?
| | RNA, Viral | 1 | 2021 | 654 | 0.030 |
Why?
| | Absorption | 1 | 1997 | 63 | 0.030 |
Why?
| | Troponin | 1 | 2017 | 50 | 0.030 |
Why?
| | Anxiety | 2 | 2021 | 1031 | 0.030 |
Why?
| | Injections, Subcutaneous | 1 | 1997 | 154 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2017 | 190 | 0.030 |
Why?
| | Models, Biological | 2 | 2010 | 1773 | 0.030 |
Why?
| | Transcriptome | 1 | 2022 | 969 | 0.030 |
Why?
| | DNA, Bacterial | 1 | 2017 | 337 | 0.030 |
Why?
| | Methemoglobin | 1 | 2015 | 21 | 0.030 |
Why?
| | Mortality | 1 | 2018 | 359 | 0.030 |
Why?
| | Forearm | 1 | 2016 | 118 | 0.030 |
Why?
| | Fear | 1 | 1999 | 338 | 0.030 |
Why?
| | Stress, Physiological | 1 | 1999 | 441 | 0.030 |
Why?
| | Acetylcholine | 1 | 2016 | 185 | 0.030 |
Why?
| | Datasets as Topic | 1 | 2016 | 119 | 0.030 |
Why?
| | Fatty Acids | 1 | 2018 | 442 | 0.030 |
Why?
| | Mental Health | 1 | 2021 | 716 | 0.030 |
Why?
| | Mice, Congenic | 1 | 2015 | 23 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2008 | 2489 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 549 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2018 | 512 | 0.030 |
Why?
| | Elasticity | 1 | 2015 | 197 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2008 | 766 | 0.030 |
Why?
| | Cause of Death | 1 | 2017 | 429 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2011 | 1462 | 0.030 |
Why?
| | Brain Chemistry | 2 | 2009 | 116 | 0.030 |
Why?
| | Sibling Relations | 1 | 2014 | 11 | 0.030 |
Why?
| | Pulse Wave Analysis | 1 | 2015 | 269 | 0.030 |
Why?
| | Urban Health | 1 | 2014 | 92 | 0.030 |
Why?
| | Regression Analysis | 1 | 1997 | 1022 | 0.030 |
Why?
| | Rural Health | 1 | 2014 | 79 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 1006 | 0.030 |
Why?
| | Inheritance Patterns | 1 | 2014 | 45 | 0.030 |
Why?
| | Mobility Limitation | 1 | 2014 | 61 | 0.030 |
Why?
| | Unsafe Sex | 1 | 2013 | 60 | 0.030 |
Why?
| | DEAD Box Protein 58 | 1 | 2013 | 9 | 0.030 |
Why?
| | Age Distribution | 1 | 2014 | 389 | 0.030 |
Why?
| | Condoms | 1 | 2013 | 103 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 2122 | 0.020 |
Why?
| | Mass Screening | 1 | 2021 | 1267 | 0.020 |
Why?
| | Survival Rate | 1 | 2017 | 1963 | 0.020 |
Why?
| | Microcirculation | 1 | 2012 | 146 | 0.020 |
Why?
| | Vasodilation | 1 | 2015 | 496 | 0.020 |
Why?
| | Research Design | 1 | 1998 | 1127 | 0.020 |
Why?
| | Genomics | 1 | 2017 | 790 | 0.020 |
Why?
| | Drug Tolerance | 1 | 1992 | 105 | 0.020 |
Why?
| | Mice | 3 | 2015 | 17757 | 0.020 |
Why?
| | Urinalysis | 1 | 2011 | 77 | 0.020 |
Why?
| | Interferons | 1 | 2013 | 202 | 0.020 |
Why?
| | Vascular Resistance | 1 | 2012 | 372 | 0.020 |
Why?
| | Infusions, Parenteral | 1 | 1991 | 40 | 0.020 |
Why?
| | Muscle Strength | 1 | 2014 | 317 | 0.020 |
Why?
| | Urban Population | 1 | 2014 | 476 | 0.020 |
Why?
| | Phobic Disorders | 1 | 2011 | 33 | 0.020 |
Why?
| | Attention Deficit and Disruptive Behavior Disorders | 1 | 2011 | 62 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2015 | 915 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2012 | 562 | 0.020 |
Why?
| | Sodium Chloride | 1 | 1991 | 142 | 0.020 |
Why?
| | Rodentia | 1 | 2010 | 57 | 0.020 |
Why?
| | Neurons | 1 | 1999 | 1587 | 0.020 |
Why?
| | Recovery of Function | 1 | 2014 | 652 | 0.020 |
Why?
| | Animals | 5 | 2015 | 36847 | 0.020 |
Why?
| | Nuclear Family | 1 | 2009 | 54 | 0.020 |
Why?
| | Fluid Therapy | 1 | 1991 | 147 | 0.020 |
Why?
| | Recurrence | 1 | 2013 | 1055 | 0.020 |
Why?
| | Mice, Inbred Strains | 1 | 2010 | 409 | 0.020 |
Why?
| | Dizziness | 1 | 2010 | 82 | 0.020 |
Why?
| | Coronary Disease | 1 | 1992 | 384 | 0.020 |
Why?
| | Alcohol-Induced Disorders, Nervous System | 1 | 2009 | 6 | 0.020 |
Why?
| | Vitamin B 6 | 1 | 2009 | 10 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2010 | 194 | 0.020 |
Why?
| | Biopsy | 1 | 2013 | 1124 | 0.020 |
Why?
| | Inflammation | 1 | 2020 | 2835 | 0.020 |
Why?
| | Fertility | 1 | 2010 | 160 | 0.020 |
Why?
| | Heptanoic Acids | 1 | 2009 | 66 | 0.020 |
Why?
| | Vitamin B Complex | 1 | 2009 | 43 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2009 | 530 | 0.020 |
Why?
| | Tetraspanins | 1 | 2008 | 19 | 0.020 |
Why?
| | Vitamin B 12 | 1 | 2009 | 128 | 0.020 |
Why?
| | Pyrroles | 1 | 2009 | 213 | 0.020 |
Why?
| | Medical History Taking | 1 | 2008 | 117 | 0.020 |
Why?
| | Receptors, Opioid, mu | 1 | 2008 | 74 | 0.020 |
Why?
| | Folic Acid | 1 | 2009 | 185 | 0.020 |
Why?
| | Sri Lanka | 1 | 2007 | 7 | 0.020 |
Why?
| | Internet | 1 | 2012 | 647 | 0.020 |
Why?
| | Preoperative Care | 1 | 2009 | 356 | 0.020 |
Why?
| | Bias | 1 | 2008 | 218 | 0.020 |
Why?
| | Disability Evaluation | 1 | 2009 | 290 | 0.020 |
Why?
| | Pakistan | 1 | 2007 | 76 | 0.020 |
Why?
| | Bangladesh | 1 | 2007 | 56 | 0.020 |
Why?
| | Energy Intake | 1 | 2010 | 484 | 0.020 |
Why?
| | Anticholesteremic Agents | 1 | 2009 | 153 | 0.020 |
Why?
| | India | 1 | 2007 | 193 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2009 | 888 | 0.020 |
Why?
| | Creatinine | 1 | 2008 | 499 | 0.020 |
Why?
| | Genes, Recessive | 1 | 2006 | 78 | 0.020 |
Why?
| | Age of Onset | 1 | 2007 | 518 | 0.020 |
Why?
| | Glucose Tolerance Test | 1 | 2007 | 364 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2008 | 1062 | 0.010 |
Why?
| | Data Collection | 1 | 2008 | 668 | 0.010 |
Why?
| | Dyslipidemias | 1 | 2007 | 176 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2010 | 1249 | 0.010 |
Why?
| | Linear Models | 1 | 2007 | 846 | 0.010 |
Why?
| | Placebos | 1 | 2005 | 199 | 0.010 |
Why?
| | 3' Untranslated Regions | 1 | 2005 | 145 | 0.010 |
Why?
| | Vitamin E | 1 | 2005 | 124 | 0.010 |
Why?
| | Heterozygote | 1 | 2005 | 293 | 0.010 |
Why?
| | Body Constitution | 1 | 2004 | 55 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2007 | 1261 | 0.010 |
Why?
| | Smoking Cessation | 1 | 2008 | 436 | 0.010 |
Why?
| | Asthma | 2 | 2010 | 2282 | 0.010 |
Why?
| | Cross-Cultural Comparison | 1 | 2004 | 87 | 0.010 |
Why?
| | Liver | 1 | 2013 | 1940 | 0.010 |
Why?
| | Fasting | 1 | 2005 | 280 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2014 | 4282 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 2 | 1999 | 2486 | 0.010 |
Why?
| | Diabetic Angiopathies | 1 | 2005 | 259 | 0.010 |
Why?
| | Hepatitis A virus | 1 | 2003 | 2 | 0.010 |
Why?
| | Chlamydophila pneumoniae | 1 | 2003 | 13 | 0.010 |
Why?
| | Interleukin-10 | 1 | 2005 | 302 | 0.010 |
Why?
| | RNA | 1 | 2010 | 921 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 5749 | 0.010 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 455 | 0.010 |
Why?
| | Asia | 1 | 2003 | 70 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2020 | 15504 | 0.010 |
Why?
| | Helicobacter pylori | 1 | 2003 | 42 | 0.010 |
Why?
| | Diabetes Complications | 1 | 2004 | 226 | 0.010 |
Why?
| | Seroepidemiologic Studies | 1 | 2003 | 165 | 0.010 |
Why?
| | Overweight | 1 | 2007 | 557 | 0.010 |
Why?
| | Antibodies, Bacterial | 1 | 2003 | 146 | 0.010 |
Why?
| | Random Allocation | 1 | 2003 | 353 | 0.010 |
Why?
| | Cytomegalovirus | 1 | 2003 | 157 | 0.010 |
Why?
| | Glucose | 1 | 2007 | 1019 | 0.010 |
Why?
| | Glucose Intolerance | 1 | 2003 | 146 | 0.010 |
Why?
| | Parents | 1 | 2010 | 1340 | 0.010 |
Why?
| | DNA | 1 | 2008 | 1458 | 0.010 |
Why?
| | Rats | 2 | 1999 | 5639 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2004 | 1282 | 0.010 |
Why?
| | Survival Analysis | 1 | 2003 | 1321 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2006 | 1163 | 0.010 |
Why?
| | Reinforcement Schedule | 1 | 1999 | 31 | 0.010 |
Why?
| | Microinjections | 1 | 1999 | 86 | 0.010 |
Why?
| | Electroshock | 1 | 1999 | 142 | 0.010 |
Why?
| | Periaqueductal Gray | 1 | 1999 | 40 | 0.010 |
Why?
| | Antibodies, Viral | 1 | 2003 | 624 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2007 | 1203 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 1999 | 185 | 0.010 |
Why?
| | Catheterization | 1 | 1999 | 179 | 0.010 |
Why?
| | Naltrexone | 1 | 1999 | 97 | 0.010 |
Why?
| | Morphine | 1 | 1999 | 158 | 0.010 |
Why?
| | Narcotic Antagonists | 1 | 1999 | 179 | 0.010 |
Why?
| | Diet | 1 | 2004 | 1274 | 0.010 |
Why?
| | Insulin | 1 | 2007 | 2406 | 0.010 |
Why?
| | Infant | 1 | 2008 | 9395 | 0.010 |
Why?
| | Child, Preschool | 1 | 2008 | 10997 | 0.010 |
Why?
| | Hyaluronoglucosaminidase | 1 | 1991 | 8 | 0.010 |
Why?
| | Tritium | 1 | 1991 | 76 | 0.010 |
Why?
| | Analgesics, Opioid | 1 | 1999 | 992 | 0.010 |
Why?
| | Depression | 1 | 1999 | 1396 | 0.010 |
Why?
|
|
McQueen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|